Published by Global Banking & Finance Review®
Posted on February 20, 2025
2 min readLast updated: January 26, 2026
Add as preferred source on Google
Indivior projects a 17% revenue drop in 2025, driven by weak Suboxone sales and generic competition, causing shares to fall by 22.8%.
(Reuters) -British drugmaker Indivior on Thursday projected a 17% fall in 2025 net revenue at the midpoint of its forecast range, partly hurt by weak sales of its film-form medication-assisted therapy for opiate addiction, sending its shares sharply lower.
Shares in the company fell as much as 22.8% to a near four-month low of 670.5 pence in early trade.
CEO Mark Crossley said the steep fall expected in 2025 net revenue was primarily due to a more than 50% drop at its opiate addiction therapy, Suboxone film, amid intense generic pricing pressures and the potential entry of a fifth generic competitor.
In October last year, Indivior issued its second profit and revenue warning in three months citing weak sales of its opioid addiction treatment Sublocade due to competition from Swedish pharmaceutical firm Camurus' drug Brixadi.
Indivior, which has a market value of just over 1 billion pounds ($1.26 billion), reported a 16% rise in adjusted operating profit to $312 million for the year ended December 31, 2024.
After a 9% increase in net revenue to $1.19 billion last year, the company expects between $955 million and $1.03 billion for 2025.
($1 = 0.7935 pounds)
(Reporting by Aby Jose Koilparambil in Bengaluru; Editing by Subhranshu Sahu)
The main topic is Indivior's projected revenue decline for 2025 and its impact on share prices.
Shares are falling due to a forecasted 17% revenue drop in 2025, driven by weak sales and generic competition.
Indivior faces challenges from intense generic pricing pressures and potential new competitors.
Explore more articles in the Finance category
